Markets:

Overview

News

Currencies

International

Treasuries

Viatris Inc. - Common Stock (NQ:VTRS)

16.29 -0.14 (-0.85%)

Streaming Delayed Price Updated: 9:56 AM EDT, Aug 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Viatris Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

VTRS Q2 Deep Dive: China Growth, Pipeline Progress, and Margin Concerns Shape Outlook

August 07, 2026

Medication company Viatris (NASDAQ:VTRS) announced better-than-expected revenue in Q2 CY2026, with sales up 4.9% year on year to $3.76 billion. The company e...

Via StockStory

Topics Economy

Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q2 CY2026

August 06, 2026

Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 4.9% year on year to $3.76 billion....

Via StockStory

Viatris (VTRS) Q2 Earnings Report Preview: What To Look For

August 04, 2026

Medication company Viatris (NASDAQ:VTRS) will be reporting earnings this Thursday before the bell. Here’s what to look for. Viatris beat analysts’ revenue ex...

Via StockStory

Topics Artificial Intelligence

Generic Pharmaceuticals Stocks Q1 Highlights: Viatris (NASDAQ:VTRS)

July 26, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how generic pharmaceutical...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Viatris (NASDAQ:VTRS) Shares Rise as Q1 Earnings Top Estimates ↗

May 07, 2026

Via Chartmill

3 Healthcare Stocks We Keep Off Our Radar

July 24, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have...

Via StockStory

3 Unpopular Stocks We’re Skeptical Of

July 20, 2026

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...

Via StockStory

1 Cash-Producing Stock with Exciting Potential and 2 Facing Headwinds

June 16, 2026

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...

Via StockStory

May 22, 2026

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...

Via StockStory

Viatris (VTRS): Buy, Sell, or Hold Post Q1 Earnings?

May 20, 2026

Viatris has been on fire lately. In the past six months alone, the company’s stock price has rocketed 58.2%, reaching $16.13 per share. This was partly thank...

Via StockStory

This Income Fund Just Completely Exited Its $37 Million Stake in Algonquin Power. Why? ↗

May 18, 2026

Algonquin serves approximately 1.3 million customer connections across the United States, Canada, Bermuda, and Chile through its regulated utility network.

Via The Motley Fool

Topics Regulatory Compliance

1 Stock Under $50 to Target This Week and 2 We Avoid

May 15, 2026

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha...

Via StockStory

5 Revealing Analyst Questions From Viatris’s Q1 Earnings Call

May 14, 2026

Viatris delivered a positive first quarter, outperforming Wall Street’s expectations on both revenue and non-GAAP earnings per share. Management attributed t...

Via StockStory

Topics Earnings

3 Unprofitable Stocks That Fall Short

May 11, 2026

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...

Via StockStory

VTRS Q1 Deep Dive: China Strength, R&D Pipeline, and Execution Drive Outperformance

May 08, 2026

Medication company Viatris (NASDAQ:VTRS) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 8.1% year on year to $3.52 bill...

Via StockStory

Viatris (VTRS) Q1 2026 Earnings Transcript ↗

May 07, 2026

Viatris (VTRS) Q1 2026 Earnings Transcript

Via The Motley Fool

These S&P500 stocks have an unusual volume in today's session ↗

May 07, 2026

Via Chartmill

What's going on in today's session: S&P500 gap up and gap down stocks ↗

May 07, 2026

Via Chartmill

Viatris’s (NASDAQ:VTRS) Q1 CY2026: Beats On Revenue

May 07, 2026

Medication company Viatris (NASDAQ:VTRS) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 8.1% year on year to $3.52 bil...

Via StockStory

Topics Artificial Intelligence

Earnings To Watch: Viatris (VTRS) Reports Q1 Results Tomorrow

May 05, 2026

Medication company Viatris (NASDAQ:VTRS) will be announcing earnings results this Thursday before the bell. Here’s what investors should know. Viatris beat a...

Via StockStory

Topics Artificial Intelligence

Natera, UFP Technologies, Mettler-Toledo, and Viatris Shares Are Soaring, What You Need To Know

April 17, 2026

What Happened? A number of stocks jumped in the afternoon session after the reopening of the Strait of Hormuz signaled a cooling of global logistics and ener...

Via StockStory

Topics Economy Government Stocks

QSM Asset Management Loads Up 611,000 Mobileye Shares ↗

April 16, 2026

Mobileye develops advanced driver assistance and autonomous driving technologies for global automotive manufacturers and suppliers.

Via The Motley Fool

Topics Economy Regulatory Compliance Supply Chain

A Fund Just Bet $5.7 Million on Robert Half -- Is the Staffing Sector Due for a Rebound? ↗

April 15, 2026

Robert Half Inc. provides staffing and risk consulting solutions globally to employers across diverse industries.

Via The Motley Fool

Topics Regulatory Compliance

QSM Asset Management Bets on Beaten-Down Manpower Group With New $5.9 Million Stake in ManpowerGroup ↗

April 15, 2026

ManpowerGroup provides staffing and HR solutions worldwide, serving clients in 75 countries.

Via The Motley Fool

Topics Regulatory Compliance

What Investors Should Know About a $24 Million Exit From a Medical Device Stock Down 9% This Past Year ↗

March 20, 2026

This medical technology firm delivers integrated blood management solutions to healthcare providers and plasma centers worldwide.

Via The Motley Fool

Topics Regulatory Compliance

1 Cash-Producing Stock to Target This Week and 2 That Underwhelm

March 17, 2026

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Via StockStory

This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision ↗

March 13, 2026

Vera Therapeutics develops biologic therapies for serious immunological diseases, with a pipeline targeting high-burden conditions.

Via The Motley Fool

Topics Regulatory Compliance

Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug ↗

March 13, 2026

Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology solutions.

Via The Motley Fool

Topics Regulatory Compliance

Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline ↗

March 13, 2026

Praxis Precision Medicines develops therapies for central nervous system disorders, targeting unmet needs in neurology and psychiatry.

Via The Motley Fool

Viatris (VTRS): Buy, Sell, or Hold Post Q4 Earnings?

March 10, 2026

Viatris has had an impressive run over the past six months as its shares have beaten the S&P 500 by 34.7%. The stock now trades at $14.11, marking a 37.8% ga...

Via StockStory

Topics Stocks

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.